Dosage Chart

BPC-157 Dosage Chart

BPC-157 dosage chart — reconstitution of a 5 mg vial, tiered subcutaneous and oral protocols with exact unit math, and injury-site guidance.

Last updated · 2026-08-04
Where to buy BPC-157
BPC-15712 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.

Reconstitution

5 mg BPC-157 vial in 2 mL bacteriostatic water

Reconstituted at 5 mg / 2 mL, the vial holds 2,500 mcg/mL. On a U-100 syringe, 10 units = 0.1 mL = 250 mcg; 20 units = 500 mcg.

The BPC-157 dosage chart covers reconstitution of a standard 5 mg vial and the tiered protocols below, with the exact unit math for each dose. BPC-157 is a stable gastric pentadecapeptide used for tendon, ligament, and gut repair.

Dosage protocols

Starter

10 units · 0.1 mL · 0.25 mg BPC-157
Once daily
Cycle: 4–12 weeks

250 mcg is a common starting dose. For a local injury, inject subcutaneously near the site; for gut or systemic healing, use abdominal subcutaneous injection or the oral route.

Your vial, your numbers

Different vial size or water volume? Recalculate your exact draw.

BPC-157 blend

Syringe Size

Draw to mark

20u(0.200 mL)

Concentration

2500 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
20u
100u syringe

From vial to injection

  1. Sanitize Wipe the BPC-157 vial stopper and the bacteriostatic-water stopper with fresh alcohol swabs and let them dry.
  2. Draw the diluent Draw 2 mL of bacteriostatic water into a reconstitution syringe.
  3. Add water slowly Angle the needle so the water runs down the inside wall of the vial rather than onto the powder.
  4. Swirl, don't shake Gently swirl until fully dissolved. Never shake.
  5. Draw your dose With a U-100 insulin syringe, draw to your tier's unit mark (10 units = 250 mcg, 20 units = 500 mcg).
  6. Inject near the target For local repair, inject subcutaneously near the injury; for gut/systemic use, inject into the abdomen or dose orally. Store reconstituted vial at 2–8 °C, use within 28 days.

Feeling something? Check here

Normal — expected
  • Mild, transient injection-site redness or itch that fades within an hour
  • No systemic effect — BPC-157 is generally well tolerated at these doses
Back off & reassess
  • Lightheadedness, headache, or nausea that persists — reduce toward the starter dose
  • Injection-site lumps or bruising lasting more than a day — rotate sites, check technique
Stop & seek care
  • Facial/throat swelling, difficulty breathing, hives — stop and seek emergency care
  • Signs of injection-site infection — spreading redness, heat, pus, fever
  • Any new or growing lump elsewhere — growth-promoting peptides are contraindicated with active or suspected cancer

General subcutaneous-peptide safety guidance; BPC-157 shows a favorable tolerability profile across the cited preclinical repair literature.

This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.

Frequently Asked Questions

How do you dose BPC-157?
Reconstitute a 5 mg vial with 2 mL bacteriostatic water (2,500 mcg/mL). Common dosing is 250–500 mcg once or twice daily — 10 units on a U-100 syringe is 250 mcg, 20 units is 500 mcg. Inject near the injury for local repair, or use abdominal subcutaneous/oral routes for gut and systemic healing; cycle 4–12 weeks.
Should BPC-157 be injected near the injury?
For a localized injury, many protocols inject subcutaneously near the site. For gut healing or systemic effect, abdominal subcutaneous injection or oral administration is used instead. It is often stacked with TB-500.
Is BPC-157 FDA-approved?
No. BPC-157 is research-use-only in the US. It was placed on the FDA's Category 2 list in 2024 and removed in April 2026 — removal is not authorization, and it is not on the 503A bulks list. Community dosing guides are a starting point, not medical advice.

Sources

⚠️ BPC-157 side effects — common, serious & how to reduce them →

Full BPC-157 research page →